TrialSignal
Clinical trial intelligence report
Validazione Italiana Dello Strumento BBI (Beaumont Behavioural Inventory) Per la Valutazione Delle Alterazioni Comportamentali Nel Paziente Affetto da Malattia Del Motoneurone
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 18, 2026
NCT ID
NCT04440644
Status
COMPLETED
Phase
N/A
Sponsor
Istituti Clinici Scientifici Maugeri SpA
Executive brief
Investment-Ready Snapshot
Up to 50% of patients affected with amyotrophic lateral sclerosis (ALS) can show behavioral dysfunctions within the spectrum of frontotemporal degenerations (FTD) - namely, apathy, disinhibition, loss of sympathy/empathy, perseverative and stereotyped behaviours, dietary changes \[Strong et al., 2017\]. The Beaumont Behavioural Inventory (BBI) \[Elamin et al., 2017\] is a questionnaire designed for detecting FTD-spectrum behavioural changes in ALS patients. The present study aims at both validating the BBI in an Italian ALS population and determining normative cut-off values of the instrument.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04440644
Indication
Amyotrophic Lateral Sclerosis
Modality
behavioral intervention
Target
BBI
Intervention
BBI
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.